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We read with interest the paper by Lip et al. (1) describing the
comparative validation of the HAS-BLED (Hypertension, Ab-
normal Renal/Liver Function, Stroke, Bleeding History or Predis-
position, Labile INR, Elderly, Drugs/Alcohol Concomitantly)
score. There are difficulties in evaluating the usefulness of new risk
models, and a simple increase of the c-statistic does not necessarily
reflect a clinically relevant improvement in describing a patient’s
risk status. Newer modeling has suggested that the net reclassifi-
cation improvement (NRI) and integrated discrimination im-
provement (IDI) be evaluated in the assessment of the usefulness
of potential biomarker(s) within an established risk-stratifying tool
(2). When comparing models, using the NRI may reveal the
advantages obtained by reclassifying a patient from one risk
category to another. Although the model in the HAS-BLED
comparative analysis seemed to be properly calibrated with the
Hosmer-Lemeshow test, the actual number of patients who were
reclassified into a different risk category (which subsequently
resulted in a change of therapy) is not specified. Therefore, the
number of reclassified patients who either were spared or experi-
enced a bleeding event was not reported. Thus, without the NRI,
it remains questionable if the reclassification yielded an improve-
ment by using the HAS-BLED model over the other schemas. If
an increase of the c-statistic does not yield a meaningful change in
a patient’s therapeutic strategy, then the utility of such testing is
not apparent. Proclaiming that the HAS-BLED score offers useful
predictive capacity for bleeding risk should not be based solely on
the area under the curve but should also include integrated
sensitivity and specificity, both components of the IDI, as well as
improvements in the reclassification tables. Therefore, although we
agree with the authors that the HAS-BLED score may provide a
valuable tool in discriminating patients based on bleeding risk,
these additional measures will offer an incremental improvement
over the c-statistic, and validate the usefulness of this score.
In addition, this combined analysis included patients treated
with ximelagatran, a direct thrombin inhibitor found to have
adverse effects on liver function testing (3). We suggest that themight be different and also may vary according to specific anatomic
sites. For example, dabigatran was associated with less intracranial
hemorrhage yet a greater risk of gastrointestinal bleeding com-
pared with warfarin in the RE-LY (Randomized Evaluation of
Long Term Anticoagulant Therapy With Dabigatran Etexilate)
study (4). This variability has implications for any future risk
model and suggests that each agent may require independent
validation in separate cohorts.
Finally, the limitation of analysis of all major bleeding in this
study to the on-treatment analysis may be less reflective of the
world outside of the clinical trial than a protocol that strictly
adheres to intention-to-treat analysis (5).
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